Equity Overview
Price & Market Data
Price: $38.47
Daily Change: -$0.60 / 1.56%
Daily Range: $37.33 - $39.13
Market Cap: $425,312,800
Daily Volume: 44,110
Performance Metrics
1 Week: 5.14%
1 Month: 49.07%
3 Months: 74.26%
6 Months: 160.6%
1 Year: 137.7%
YTD: 220.5%
Company Details
Employees: 14
Sector: Health technology
Industry: Biotechnology
Country:
Details
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania